Age-Related Differences in Plasma Proteins: How Plasma Proteins Change from Neonates to Adults by Ignjatovic, Vera et al.
Age-Related Differences in Plasma Proteins: How Plasma
Proteins Change from Neonates to Adults
Vera Ignjatovic1,2*, Cera Lai1,2, Robyn Summerhayes1,2, Ulrike Mathesius3, Sherif Tawfilis4, Matthew A.
Perugini5, Paul Monagle1,2,6
1Murdoch Childrens Research Institute, Royal Children’s Hospital, Parkville, Victoria, Australia, 2Department of Paediatrics, The University of Melbourne, Royal Children’s
Hospital, Parkville, Victoria, Australia, 3 Research School of Biology, Australian National University, Canberra, Australian Capital Territory, Australia, 4GE Healthcare Life
Sciences Australia, Bundoora, Victoria, Australia, 5Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, The University
of Melbourne, Parkville, Victoria, Australia, 6Department of Clinical Haematology, Royal Children’s Hospital, Parkville, Victoria, Australia
Abstract
The incidence of major diseases such as cardiovascular disease, thrombosis and cancer increases with age and is the major
cause of mortality world-wide, with neonates and children somehow protected from such diseases of ageing. We
hypothesized that there are major developmental differences in plasma proteins and that these contribute to age-related
changes in the incidence of major diseases. We evaluated the human plasma proteome in healthy neonates, children and
adults using the 2D-DIGE approach. We demonstrate significant changes in number and abundance of up to 100 protein
spots that have marked differences in during the transition of the plasma proteome from neonate and child through to
adult. These proteins are known to be involved in numerous physiological processes such as iron transport and
homeostasis, immune response, haemostasis and apoptosis, amongst others. Importantly, we determined that the proteins
that are differentially expressed with age are not the same proteins that are differentially expressed with gender and that
the degree of phosphorylation of plasma proteins also changes with age. Given the multi-functionality of these proteins in
human physiology, understanding the differences in the plasma proteome in neonates and children compared to adults will
make a major contribution to our understanding of developmental biology in humans.
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Introduction
Plasma is a complex biological system and the plasma proteome
contains proteins from a variety of cellular localizations, including
intracellular and membrane proteins secreted in plasma as a result
of cell lysis and cellular turn-over [1]. This system is considered the
most informative proteome by clinicians, because it communicates
with most cells in the body and hence many disease states tend to be
reflected by changes in plasma proteins. Proteomic studies to date
have focused on investigation of biomarkers, as well as determining
the effects of drugs on various proteomes. The majority of such
studies have focused on adults, with very limited investigation of the
proteome in neonatal and paediatric population. In children,
proteomics has been used to examine changes in expression levels of
proteins that occur during Cardiopulmonary Bypass Surgery [2]. A
specific approach of proteomics, that uses two-dimensional (2D) gel
technology has been used in the paediatric setting, to investigate a
number of disease states including: blood disorders [3], sickle cell
disease [4], leukemia [5] and cystic fibrosis [6].
The protein diversity of the human plasma proteome has been
demonstrated in adults [7], as well as in fetuses, newborns and
children [8]. However, the proteins in question were not directly
identified and instead, the identity of each protein was based on
the position of the protein within the 2-D gel and previously
identified proteins from adult samples.
Human ProteomeOrganization (HUPO) Plasma Proteome Project
(PPP) recognizes the importance of analyzing and understanding age-
related differences in the plasma proteome by identifying this as one of
their scientific aims and research priorities [9].
This study accessed plasma samples from healthy neonates
through to adults and accordingly is the first study to investigate
the physiological development of the human plasma proteome by
examining the quantitative and qualitative changes that occur with
age. The results provide an insight into the function of this
complex biological fluid, as well as the processes of growth, deve-
lopment and ageing of the plasma proteome.
Methods
Sample information
Written informed consent was obtained and the study was
approved by the Royal Children’s Hospital Ethics in Human
Research Committee (#20031E) and the Royal Women’s
Hospital Human Research Ethics Committee (#02/08). The
consent was by provided by a parent or guardian for participants
under the age of eighteen.
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Six individual samples (3 males and 3 females) from each of the
seven age-groups (Day1 neonates, Day 3 neonates; ,1, 1–5, 6–10
and 11–16 years of age and adults) were used for this analysis.
Plasma samples were obtained from healthy children about to
undergo elective surgery at the Royal Children’s Hospital. These
children were healthy other than the need for elective surgery (i.e.
tongue tie release), were not receiving any medications and had no
significant family history of major diseases, particularly diseases
known to be associated with the process of ageing. Neonatal
samples (day 1 and day 3 post-birth) were collected from healthy
term neonates from the Family Birthing Unit or post-natal wards
at the Royal Women’s Hospital, Melbourne. Eligibility criteria
included: gestation .37 weeks, vaginal delivery, birth-weight
.2500 gm, APGAR at 5 min$7 and absence of systemic
abnormalities. Adults (21–43 years of age) were healthy volunteers
on no medications, and similarly, with no past medical history.
Blood samples were collected in S-MonovetteH tubes (Sarstedt,
Australia), containing 1 volume of citrate per 9 volumes of blood
and were centrifuged at 3000 rpm, 10 minutes, 10uC (Megafuge
1.0R, Heraeus), with plasma stored at 285uC, until testing.
Plasma samples were depleted of Albumin and IgG using the
Albumin IgG removal kit (GE Healthcare, Rydalmere, Australia).
The remaining proteins were precipitated using acetone precip-
itation, as specified in the depletion kit and were re-suspended in
buffer containing 7 M urea, 2 M thiourea, 4% CHAPS and
30 mM Tris. Protein content of each sample was quantified using
the Bradford assay (Bio-Rad, Hercules, CA, USA).
2D- Difference In Gel Electrophoresis (DIGE)
The internal standard consisted of an equal amount of each one
of the 42 samples, was labeled with the Cyanine 2 (Cy2) dye (GE
Healthcare, Rydalmere, Australia) and run on each gel to control
for gel-to-gel variation. For each age-group, 3 samples were
labeled with Cy3 and 3 samples with Cy5, with the samples then
randomized to 42 gels run during this project (21 gels for pH 3–
11; 21 gels for pH 4–7).
The Cy2, Cy3 and Cy5 samples (50 mg of sample/400 pmol of
Cy dye) for each gel were pooled and loaded onto the 1st
Dimension Immobilized pH Gradient (IPG) Strip. The 24 cm,
pH 3–11 and pH 4–7, non-linear Immobiline Drystrips (GE
Healthcare, Rydalmere, Australia) were rehydrated with 15 ml
IPG buffer 3–11/4–7 NL and 3 ml DeStreak solution (GE
Healthcare, Rydalmere, Australia). Isoelectric focusing was carried
out using the Multiphor II Isoelectric Focusing system (GE
Healthcare, Rydalmere, Australia).
The IPG strips were conditioned for 15 min in equilibration
buffer containing 2% Sodium Dodecyl Sulphate (SDS), 50 mM
Tris(hydroxymethyl)aminomethane (Tris)-HCl, pH 8.8, 6 M urea,
30% glycerol, 0.002% bromophenol blue, and 10 mg/mL
dithiothreitol (DTT). The strips were then alkylated for 15 min
in equilibration buffer containing 25 mg/mL iodoacetamide
instead of the DTT and loaded onto 12.5% polyacrylamide gels
which were cast according to specifications by GE Healthcare.
Second dimension was run using the Ettan Dalt 6 system
(GE Healthcare, Rydalmere, Australia), for an average of
4.5 hours, until the bromophenol blue dye-front reached the edge
of the gels.
Gel Imaging
Gels were scanned using the Typhoon Trio variable mode
imager (GE Healthcare, Rydalmere, Australia), with a resolu-
tion of 100 mm, and PMT of 500/600 V. Gels representing pH 3–
11 were grouped and analyzed separately to gels representing
pH 4–7.
Gel Data Analysis
Data obtained from the gels was quantified using the DeCyder
version 6.5 software (GE Healthcare, Rydalmere, Australia). The
Differential In-gel analysis (DIA) was used to optimize spot
detection. The Biological Variation Analysis (BVA) module was
used for analysis of each sample according to the corresponding
age-group. The filtering parameters were set to determine the
spots that: had a p-value#0.05 for the t-test (one way analysis of
Variance ANOVA) employed to test the variation between age-
groups and a.1.5 fold change in abundance between the groups.
Spot excision and identification
Proteins of interest were excised from 2-D gels robotically using
the Ettan Spot-picker (GE Healthcare, Rydalmere, Australia). Gel
pieces were digested initially with 10 mL of 4 ng/mL endoprotease
1 (Lys-C) from Achromobacter lyticus (Wako Chemicals, Osaka,
Japan) in 25 mM NH4HCO3, pH 9.0, overnight at 20uC and
subsequently with 10 mL of 4 ng/mL sequencing grade porcine
trypsin (Promega, Madison, WI, USA) in 25 mM NH4HCO3,
pH 9.0 for 30 min at 37uC. The resulting peptides were acidified
with 2 mL of 10% trifluoroacetic acid (TFA) and extracted by
sonication. The peptides were purified using C18 reversed-phase
ZipTips (Millipore Corp., Bedford, USA). Peptides were eluted
with 5 mL 70% acetonitrile in 0.1% TFA for Matrix-assisted laser
desorption/ionization – Time of Flight/Time of Flight (MALDI-
TOF/TOF) analysis. A 0.5 mL sample aliquot was spotted onto a
sample plate, which was pre-spotted with 0.5 mL of matrix (8 mg/
mL a-cyano-4-hydroxycinnamic acid in 70% v/v acetonitrile and
0.1% TFA) and allowed to air dry. MALDI TOF/TOF analysis
was performed with an Applied Biosystems 4800 Proteomics
Analyser (Australian Cancer Research Foundation Biomolecular
Resource Facility, The Australian National University, Canberra).
The peak list-generating software used was AB MDS SCIEX 4000
Series Explorer version 3.5.1.
Spectra were acquired in Mass Spectrometry (MS) reflector
mode over the m/z range of 800–3500 Da with internal
calibration to trypsin autolytic peptides. The instrument was then
switched to MS/MS mode where the 7 strongest peptides
(excluding known contaminant peptides) from the MS scan were
selected and fragmented using the Collision Induced Dissociation
(CID) at low pressure and their mass and intensities were
measured. A near point external calibration was applied for the
MS/MS spectra and gave a typical mass accuracy of ,50 ppm or
less. Analysis of peptide data was performed using the Human
International Protein Index version 3.49 and Protein Pilot version
2.0 (AB MDS SCIEX) databases. The number of protein entries
searched was 74013, the cut-off score was .1.3 and the proba-
bility score of 95% that a protein is correct was used for accepting
individual MS/MS spectra.
Extended Data Analysis (EDA)
The EDA component of the DeCyder software (GE Healthcare,
Rydalmere, Australia) was used for more specific analysis of the
expression patterns of the plasma proteome proteins across the
seven age-groups. Hierarchical clustering was used to group
protein expression changes of differentially abundant proteins
across the age-groups.
Western blot validation
The validation of the protein abundance observed using 2D-
DIGE was performed using western blotting. Pooled plasma
samples containing equal amounts of protein from 6 individuals
for each of the 7 age-groups were diluted 1:100 using Phosphate
Ageing of the Human Plasma Proteome
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Buffered Saline (PBS) and were run on 12% Tris-HCl SDS-
Polyacrylamide Gel Electrophoresis (PAGE) gels (Bio-Rad,
Australia) and transferred onto Amersham Hybond-P Polyvinyli-
dene Fluoride (PVDF) membranes (GE Healthcare, Australia)
using previously described method [10]. Membranes were
immunoblotted with the sheep anti-human fibrinogen peroxidase
conjugated IgG monoclonal antibody (SAFG-APHRP) or the goat
anti-human alpha-2-macroglobulin peroxidase conjugated IgG
monoclonal antibody (GAA2M-APHRP), at a dilution of 1:10000
(Affinity Biologicals, Ontario, Canada). Fibrinogen and alpha-2-
macroglobulin were visualized using the Electrochemilumines-
cence (ECL) Advance Western Blotting Detection Kit and images
acquired using the Typhoon Trio variable mode imager, both
from GE Healthcare. Quantification of the relative abundances
was performed using the 1D gel analysis module from the
ImageQuant TL version 7.0 software (GE Healthcare, Rydalmere,
Australia).
Phosphoproteome analysis
Age-related differences in phosphorylation of plasma proteins were
determined by studying the plasma phosphoproteome for Day 1
neonates and Adults (N=6 individual samples pooled for each group).
Figure 1. Comparison of the protein pattern from a representative 2D-DIGE gel of human plasma proteins. A: Cy3 stained Day 1
sample; B: Cy5 stained Adult sample; C: Image overlay (Cy3 - green, Cy5 - red, Identical areas – yellow). pH 3–11 left to right.
doi:10.1371/journal.pone.0017213.g001
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Individual samples were depleted of Albumin and IgG, precipitated,
re-suspended and quantified according to instructions above. 50 mg of
sample from each of the two pools was used for the duplicate gel run.
2D-DIGE, image acquisition and analysis were performed according
to the methods described earlier. Gels were stained with the Pro-Q
Diamond phosphoprotein stain (Molecular Probes, Oregon, USA)
according to instructions provided by the manufacturer. Pro-Q
Diamond stained gel images were acquired using the Typhoon Trio
– Variable mode imager (GE Healthcare, Rydalmere, Australia):
excitation at 532 nm; emission filter-580 BP 30. Gel images were
processed and matched to the master gel from the original workspace.
Only proteins with known identities were considered. Cy5 (total
protein) and Cy3 (quantity of phosphorylation) images and spot profiles
of proteins were compared to determine the phosphorylation status. In
the case of the protein being highly phosphorylated, the ratio of
Cy5:Cy3 spot volume is expected to be approximately 1.
Results
Protein spot maps and protein identity
Approximately 1000 protein spots were detected on each gel.
Up to 100 (10%) protein spots were found to be significantly
different in abundance across various age-groups tested (Day 1 and
Day 3 neonates,,1 year, 1–5, 6–10 and 11 to 16 year old children
as well as adults) and occurred in more than 75% of the replicates.
A representative spot pattern for a day 1 neonate and an adult
sample are shown in Figure 1A and 1B respectively. Some of the
obvious differences between the two samples are highlighted in
both figures (circles), while the overlay in Figure 1C also highlights
the differences between a plasma proteome for a Day 1 neonate
and an Adult. The proteins that are less abundant in the neonatal
sample are presented in red (Figure 1C) and the identified proteins
are presented in Table 1; while the proteins that are more
abundant in the neonatal sample are presented in green
(Figure 1C) and the identified proteins are listed in Table 2.
Some of the proteins that were present in neonatal plasma and
absent from adult plasma and vice versa are as yet unidentifiable.
Consideration of individual proteins
The location of proteins whose abundance changes significantly
with age is shown in Figure 2A. An example of one such protein,
fibrinogen beta chain, is shown in Figure 2B, with the age-related
change in abundance for that protein demonstrated in Figure 2C.
The age-specific abundance pattern for fibrinogen determined
using the 2D-DIGE was validated using a fibrinogen specific
antibody (Figure 3). The western blot validation was also
performed for alpha-2-macroglobulin using a monoclonal anti-
body (Figure 4). In both cases, the age-related variation was
consistent between the two methods employed.
Gender specific analysis
The analysis of the protein abundance data based on gender of
the participants demonstrates that 15 (0.87%) to 26 (1.8%) of the
protein spots detected have significantly different abundance (1-
ANOVA,0.05 and average ratio $1.5 or #21.5) based on a
gender analysis only, for pH 3–11 and pH 4–7 respectively.
Table 1. Differentially expressed protein spots identified from the 2D-DIGE profiling of human plasma, with lower abundance in
neonates and children compared to adults.
Protein
Master
Number Protein Name
Accession
number
One way
ANOVA
Protein
Score
Protein Score
C.I. %
1 608 Clusterin P10909 2.92E-05 130 100
2 272 Isoform 2 of Fibrinogen alpha chain P02671 4.80E-03 65 97.6
3 601 Isoform 2 of Fibrinogen alpha chain P02671 2.21E-03 251 100
4 353 Isoform 2 of Fibrinogen alpha chain P02671 0.0197 151 100
5 327 Isoform 2 of Fibrinogen alpha chain P02671 0.0208 268 100
6 342 Isoform 2 of Fibrinogen alpha chain P02671 0.0118 323 100
7 823 Fibrinogen beta chain P02675 3.27E-03 139 100
8 477 Haptoglobin P00738 1.85E-03 134 100
9 554 cDNA FLJ31310fis; Haptoglobin B3KP77 8.07E-04 119 100
10 511 cDNA FLJ31310fis; Haptoglobin B3KP77 2.04E-03 61 94.4
11 487 cDNA FLJ31310fis; Haptoglobin B3KP77 2.53E-03 182 100
12 557 Haptoglobin isoform 2 preproprotein P00739-2 1.37E-03 218 100
13 523 Haptoglobin isoform 2 preproprotein P00739-2 1.95E-03 79 99.9
14 598 Isoform 1 of alpha-1-antitrypsin P01009-1 1.37E-03 214 100
15 874 Hemopexin precursor P02790 0.0016 71 98.273
16 825 Kininogen 1 Variant P01042 0.004 111 100
17 866 Kininogen 1 Variant P01042 0.0033 118 100
18 826 Kininogen 1 Variant P10402 0.0062 82 99.869
19 855 Chain A, Cleaved Alpha1 -Antichymotrypsin P01011 0.033 188 100
20 821 Hemopexin precursor P02790 0.0078 236 100
21 277 Chain A, Human Factor H P14210 0.048 428 100
Proteins were identified using MALTI-TOF/TOF. IPI – International Protein Index human accession number. Protein spots 1–14 were identified from pH 3–11 gels; Protein
spots 15–21 were identified from pH 4–7 gels. Protein score reflects the combined scores of all observed mass spectra that can be matched to amino acid sequences
within a specific protein; higher score indicates a more confident match.
doi:10.1371/journal.pone.0017213.t001
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Proteins with common expression patterns
The hierarchical clustering of the different age-groups, taking
into account only the protein spots that were differentially
abundant across all age-groups is represented in Figure 5. For
the proteins that are significantly different in abundance across the
seven age-groups, adults are closely related to the less than one
year olds and that Day 1 and Day 3 neonates are closely linked to
the 1 to 5 year old age-group.
Differences in the phosphoproteome of neonatal and adult
plasma are highlighted in Figure 6. From the plasma proteins with
confirmed identification, 16 proteins were determined to be
phosphorylated in each age-group (Table 3), with two proteins
being specific to the neonatal group and an additional two proteins
specific to the adult group. Based on the spot volume ratios (Cy5
(total)/Cy3 (phosphorylated)) proteins in the adult age-group were
more phosphorylated compared to neonates.
Discussion
The results of this study provide important insights into plasma
proteome changes accompanying normal growth and develop-
ment. The differences in the plasma proteome with age are evident
across the seven age-groups tested and for samples collected using
specific inclusion criteria.
The sample size in our study is based on studies that investigated
the plasma proteome [11,12], as well as other proteomes [13,14]. The
carefully controlled selection of subjects in this study, as well as
standardized blood collection, processing and storage protocol across
all age-groups minimized the variation of external factors.
In addition to the age-specific differences, we confirm for the
first time that up to 1.8% of the plasma proteome differences can
be attributed to the gender of the participant. Importantly
however, the proteins differentially expressed based on gender
were not those proteins that were differentially expressed with age,
leading to the conclusion that age-related changes in the plasma
proteome are not a function of sexual maturity.
Some of the proteins contributing to this concept of ‘‘ageing’’ of the
plasma proteome are known to be involved in iron transport and
homeostasis, immune response, haemoglobin binding, serum protein
transport, haemostasis, cholesterol metabolism, actin filament
assembly and disassembly, clearance of cellular debris and apoptosis,
regulation of muscle contraction as well as maintenance of osmotic
pressure. This implies that the process of ageing is a multi-factorial,
complex process that involves many processes which should be
considered when studying diseases of ageing.
Post-translational modifications, particularly phosphorylation,
may contribute to age-related changes in protein expression in
plasma. This is the first study to demonstrate an age-related
increase in protein phosphorylation in adult compared to neonatal
plasma, suggesting that this difference in phosphorylation could be
a function of age. Whether increased protein phosphorylation is in
any way linked to an increasing prevalence of diseases in adults
needs to be investigated further especially given the instrumental
role of phosphorylation in modulating protein structure and
function and the regulation of signalling pathways. It is
particularly important to determine whether differences in the
plasma phosphoproteome observed between neonates and adults
persist throughout childhood.
Table 2. Differentially expressed protein spots identified from the 2D-DIGE profiling of human plasma, with higher abundance in
neonates and children compared to adults.
Protein
Master
Number Name
Accession
number
One way
ANOVA
Protein
Score
Protein Score
C.I. %
1 100 Alpha-2-macroglobulin P01023 1.37E-03 35 100
2 12 Alpha-2-macroglobulin P01023 7.84E-03 251 100
3 149 Complement C3 (fragment) P01024 9.08E-03 139 100
4 483 Complement C3 P01024 5.90E-03 298 100
5 333 Complement Factor B P00751 5.48E-03 223 100
6 322 Isoform 2 of Fibrinogen alpha chain P02671 4.06E-04 376 99.9
7 314 Isoform 2 of Fibrinogen alpha chain P02671 5.41E-03 124 100
8 393 Fibrinogen beta chain P02675 0.0113 153 100
9 335 Fibrinogen beta chain P02675 3.86E-03 144 100
10 425 Isoform Gamma-A of
Fibrinogen gamma chain
P02679 6.92E-03 114 100
11 345 Vitamin D-binding protein P02774 4.14E-03 136 100
12 30 Fibronectin 1 variant P02751 0.043 408 100
13 426 Alpha 2 macroglobulin variant P01023 0.011 517 100
14 470 Chain B, Complement Component C3b P01024 0.032 525 100
15 708 Chain A, Heparin Cofactor II P05546 0.0087 147 100
16 940 Alpha-1-antichymotrypsin P01011 0.012 183 100
17 416 Chain A, Bikunin From the
Inter-Alpha Inhibitor Complex
P02760 0.04 88 99.963
18 427 Chain B, Complement Component C3 P01024 0.027 103 99.999
19 150 Alpha-2-macroglobulin P01023 0.0077 91 99.984
Proteins were identified using MALTI-TOF/TOF. IPI – International Protein Index accession number. Protein spots 1–11 were identified from pH 3–11 gels; Protein spots
12–19 were identified from pH 4–7 gels. Protein score reflects the combined scores of all observed mass spectra that can be matched to amino acid sequences within a
specific protein; higher score indicates a more confident match.
doi:10.1371/journal.pone.0017213.t002
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The results of this study demonstrate a quantitative increase in
fibrinogen in neonates (Day 1 and Day 3) compared to adults, a
result that was validated using the western blot methodology.
Fibrinogen plays an essential role in haemostasis, and is important
for the formation of a stable clot. In addition, fibrinogen has also
been shown to play an important role in the in the innate immune
system, demonstrating the important interplay between hemostatic
and inflammatory pathways [15–18]. Increased fibrinogen levels in
neonates (Day 1 and Day 3) could play a role in the immune
response that takes place immediately after birth. Age-specific
reference ranges for fibrinogen are based on a functional assay, and
although they demonstrate an increase in the functional activity of
fibrinogen in infants and children up to 5 years of age [19], this is the
first study to demonstrate age-related quantitative changes in
fibrinogen. The fact that increased fibrinogen levels in neonates are
not reflected by increased fibrinogen activity at this particular age,
suggests a possible variation in the structure of this molecule in
neonates and whether this could be a result of specific PTMs is still
Figure 2. Example of protein that changes with age. (A) Representative gel image showing locations of proteins that are differentially
expressed across age, $1.5 change in abundance; p,0.05; (B) 3-D view example of a spot that is up-regulated with age (number 823); (C) expression
pattern for spot 823 (Fibrinogen beta chain) across seven age-groups; y-axis represents log abundance.
doi:10.1371/journal.pone.0017213.g002
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to be confirmed. This is certainly a relevant hypothesis, particularly
with the knowledge that a ‘‘foetal’’ form of Fibrinogen exists in the
first six month following birth, and has an increased sialic acid
content compared to the adult form of the protein [20].
The abundance of alpha-2-macroglobulin was increased in
neonates and children, compared to adults, a result which is
consistent with previous evidence that alpha-2-macroglobulin
quantity decreases with age [21]. Since, the incidence of
thromboembolic events is significantly decreased in healthy
neonates and children compared to adults, the increased expression
of alpha-2-macroglobulin in early age may be one of the factors
contributing to the overall thromboprotective state observed in
childhood. Furthermore, the decline in alpha-2-macroglobulin with
increasing age could be explained by the genetic association
between alpha-2-macroglobulin polymorphisms in Alzheimer’s
disease. Specifically, the underlying assumption is that the (5 base
pair intronic) deletion in the Alpha-2-macroglobulin gene may
affect the functionality and quantity of the resultant Alpha-2-
macroglobulin protein in circulation, therefore contributing to
Alzheimer’s disease pathology [22]. Alternatively, it is possible that
Figure 3. Validation of the age-specific variation in fibrinogen. (A) western blot image; (B) quantification (mg) of the western blot; (C) 2D-DIGE
calculated relative log abundance.
doi:10.1371/journal.pone.0017213.g003
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neither genetic predisposition nor Alpha-2-macroglobulin quantity
contribute towards the pathology of Alzheimer’s disease, but rather
differences in post-translational modification of this protein. Taking
into account that there is currently no cure available to treat this
incapacitating disease, the observed age-related decrease in
abundance of alpha-2-macroglobulin with advancing age might
prove to be relevant to Alzheimer’s disease pathology and thus
provides a potential focus for future research.
The increased expression of plasma Alpha-1-antichymotrypsin
in neonates and children compared to adults is a novel finding, as
age-specific reference ranges for Alpha-1-antichymotrypsin in
neonates and children have not been reported to date. Alpha-1-
antichymotrypsin deficient plasma (due to a point mutation in the
Alpha-1-antichymotrypsin gene) is associated with a predisposition
to chronic pulmonary obstructive disorders [23,24]. This is
confirmed by Alpha-1-antichymotrypsin’s role as a protease
inhibitor in the defence against degradation by proteases in the
lower respiratory airways [25]. Therefore, observed age-related
decrease in plasma Alpha-1-antichymotrypsin in the current study
is consistent with the increased prevalence of chronic obstructive
pulmonary disorders in the adults compared to neonates and
children [26]. Whether this decrease in Alpha-1-antichymotrypsin
with age may be a causative or an associated phenomenon with
disease should be determined with further studies.
Figure 4. Validation of the age-specific variation in alpha-2-macroglobulin. (A) western blot image; (B) semi-quantification of the western
blot (densitometry units); (C) 2D-DIGE calculated relative log abundance.
doi:10.1371/journal.pone.0017213.g004
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The abundance of Kininogen was increased in adults compared
to neonates and children. This finding that the abundance of
Kininogen increases with age is consistent with the knowledge that
elevated levels of plasma Kininogen are associated with diseases of
ageing, such as vascular disease and thromboembolism [27],
rheumatoid disease [28], Paget’s disease [28] and also with
increased risk of myocardial infarction [29]. Whether increased
levels of Kininogen may prove to be a potential marker for
detection of certain diseases remains to be determined.
Increased expression of the vitamin D binding protein in
neonates and children compared to adults is novel and important,
particularly with the knowledge that higher vitamin D circulating
concentrations are associated with a lower risk of chronic illnesses
such as common cancers as well as cardiac diseases [30].
Another novel finding of this study relates to clusterin, which we
show to have decreased expression in neonates and children compared
to adults. The expression of clusterin, also known as apolipoprotein J is
known to be induced by processes such as oxidative stress, as well as
apoptotic stimuli and this protein has also been implicated in inhibition
of neuroblastoma cell invasion [31]. Considering that these processes
are stimulated by ageing, our observation of age-related increase in
abundance of clusterin confirms the relevance of this protein in the
process of ageing and suggests another avenue for future research.
The results of the cluster analysis seem to be counter-intuitive,
with Day 1 and Day 3 neonates linking more closely to the 1–5 year
old age-group, rather than to the,1 year old age-group. However,
these results are based only on the differentially abundant proteins,
not the detected plasma proteome as a whole and demonstrate that
the neonatal age-groups in general have more proteins that are
found in lower abundance compared to other age-groups.
The potential limitations of the study include the number of the
samples tested, as well as the fact that the method chosen is one of a
number of methods available at present, all of which do not
represent the whole, but only a part of the plasma proteome. In the
future, methods might become available to investigate the complete
plasma proteome. However, this is not a viable option at present.
Figure 5. Hierarchical clustering of differentially abundant proteins across the age-groups. Relative expression patterns of each protein
are expressed as a heat map ranging from 20.5 (green) to +0.5 (red), including proteins identified in Table 1 and Table 2.
doi:10.1371/journal.pone.0017213.g005
Figure 6. Overlay of gel stained with Pro-Q Diamond Phosphoprotein Stain. Circled areas represent regions with differences in
phosphorylation patterns between (A) Day 1 neonates and (B) adult samples. Red (Cy5) represents the total plasma proteome; Green (Cy3) represents
the phosphoproteome.
doi:10.1371/journal.pone.0017213.g006
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Despite these limitations, our study suggests age-related changes in
protein abundance and phosphorylation is common amongst a
number of plasma proteins. The functional implications of these
changes remains to be determined and likely has major implications
for our understanding of the role of these proteins in a wide range of
physiological functions during growth and development. In
addition, given that the incidence of the majority of diseases (i.e.
diabetes, cardiovascular disease, cancer) increase with age, this
study provides the basis for identification of potential biomarkers
and therapeutic targets for numerous disease processes.
By understanding the age-specific development of the plasma
proteome, future investigations can focus on disease related
processes in this complex biological fluid.
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Table 3. Phosphorylated proteins.
PROTEIN
Day1
Neonates Adults
Alpha-1-antichymotrypsin precursor 19.46 -
Alpha-1-antichymotrypsin 3.04 1.03
Alpha-1B-glycoprotein 5.37 1.44
Antithrombin 6.28 2.27
Apo Serum Transferrin 9.54 1.37
Bikunin 3.61 24.29
Complement 3b 14.92 -
Fibrinogen gamma 5.77 1.83
Haptoglobin 2.45 1.59
Hemopexin precursor 10.89 3.01
Inter-alpha (globulin) inhibitor H4 1.61 2.43
Kininogen 29.62 23.66
Prothrombin 4.79 1.25
Vitamin D Binding protein 12.36 3.9
Alpha-1-antitrypsin precursor - 6.01
Complement 9 - 3.04
Results represent the spot volume ratio for total (Cy5) compared to
phosphorylated (Cy3) protein. (-) Proteins that are not detectable in a particular
age-group.
doi:10.1371/journal.pone.0017213.t003
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